Clinical trials: Cancer, Head
Head and Neck Cancer
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for larynx cancer.
- Trial name
- NCT02759575
- Testing
- Pembrolizumab, Radiation Therapy, Cisplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vinita Takiar
Head and Neck Cancer, Precancerous Condition
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01084083
- Testing
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel
- Where
- 121 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eastern Cooperative Oncology Group
Lobular Breast Carcinoma
Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT
Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due to the poor accumulation of 18F-FDG in the tumour.
- Trial name
- GALILEE (NCT05931302)
- Testing
- 68Ga-FAPI-46 PET scan
- Where
- Monaco
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Head and Neck Cancer
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00095875
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 15 sites in United States, Germany
- Volunteers
- 145 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Neoplasms
Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Esophageal Neoplasms.
- Trial name
- IRE (NCT02430701)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Esophageal Cancer, Gastric Cancer
Molecular Assessment for Gastro-Esophageal Cancer
The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for…
- Conditions
- Esophageal Cancer, Gastric Cancer, Barrett Esophagus
- Trial name
- MAGEC (NCT06346054)
- Testing
- Breath analysis, Blood analysis
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Malignant Neoplasm of Head of Pancreas
Billroth II or Roux-en-Y Reconstruction for GJ After PD: Randomized Controlled Trial (PAUDA TRIAL)
The aim of the study is to compare the effect of Roux-en Y reconstruction (study group, DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for DPC.
- Trial name
- PAUDA (NCT02246205)
- Testing
- Pancreaticoduodenectomy
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Universitari de Bellvitge
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Patients With Non-curable Head and Neck Cancer
The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer
- Trial name
- NCT00382031
- Testing
- Zalutumumab, Control
- Where
- 82 sites in Belgium, Brazil and 10 more
- Volunteers
- 286 people
- Sponsor
- Genmab
Nasopharyngeal Carcinoma
Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is usually treated with chemoradiotherapy. While the effects of this treatment on cochlear function is well characterized, its effect on vestibular function is not well studied.
- Trial name
- NCT02505672
- Testing
- Chemoradiotherapy for nasopharyngeal carcinoma
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rabin Medical Center
Erythroplakia, Hyperplasia
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia).
- Conditions
- Erythroplakia, Hyperplasia, Oral Cavity Carcinoma, Oral Leukoplakia
- Trial name
- NCT02581137
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride
- Where
- 4 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer
Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
This phase II trial studies how well thyroid gland removal with or without central lymph node dissection works in treating patients with thyroid cancer or suspected thyroid cancer that has not spread to the lymph nodes…
- Conditions
- Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage III Papillary Thyroid Cancer
- Trial name
- NCT02138214
- Testing
- Thyroidectomy, entral lymph node dissection (CLND), Quality-of-life assessment
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Wisconsin, Madison
Cancer of Head and Neck, Smoking
Assessment of Early Genetic Changes in Smokers
This study will look at the genetic profile of cells taken from the oral cavity of healthy college students who smoke and who do not smoke cigarettes.
- Trial name
- NCT00200408
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Head and Neck Squamous Cell Carcinoma, Selenium
Sodium Selenite Supplementation in Patients With Head and Neck Cancer
The micronutrient selenium is an essential trace element in the human body. There are more than 25 proteins in the human body contain selenium, such as glutathione peroxidase and selenoprotein, which regulate the body's…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Selenium, Sodium Selenite
- Trial name
- NCT05451576
- Testing
- Zelnite®
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Squamous Cell Carcinoma, Human Papilloma Virus (HPV)
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC).
- Conditions
- Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- Trial name
- NCT07513389
- Testing
- Active Surveillance With ctHPVDNA (NavDx®)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Upper Aerodigestive Tract Neoplasms, Lung Cancer
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment
This is a multicenter, interventional, randomized study among patients with a first lung or head \& neck cancer who are still active smokers ± alcohol misusers.The study will aim to compare the systematic implementation of an…
- Trial name
- ALTAKRA-1405 (NCT02540174)
- Testing
- integrated addiction treatment program, standard of care
- Where
- 3 sites in France
- Volunteers
- 133 people
- Sponsor
- Centre Oscar Lambret
Prostate Cancer, Bladder Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT00199849
- Testing
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Head and Neck Squamous Cell Carcinoma
Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study
Head and neck squamous cell carcinoma are frequent. The chemoradiotherapy protocols are part of the reference treatment of locally advanced stage tumors.
- Trial name
- ORODIFF (NCT02862678)
- Testing
- diffusion-weighted MRI
- Where
- France
- Volunteers
- 59 people
- Sponsor
- CHU de Reims
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
Brief Summary Study title: Indocyanine green (ICG)-guided omental shield anastomosis (ICG-OSA) technique for cervical esophagogastric anastomosis in esophageal cancer surgery Purpose: To evaluate whether a novel surgical…
- Trial name
- NCT07376876
- Testing
- Indocyanine green-guided omental shield anastomosis for cervical esophagogastric anastomosis
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Esophageal Squamous Cell Carcinoma
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC
- Trial name
- NCT01854749
- Testing
- S1 combined with cisplatin
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Fudan University
Thyroid Cancer
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Background: Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells.
- Trial name
- NCT06991738
- Testing
- 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.